| Target Professions: | DO, MD, Nurse Practitioner, Physician Associate/Assistant |
| Target Specialties: | Allergy and Immunology, Dermatology, Pediatrics |
| Credits Available: | 7.25 AMA PRA Category 1 Credit™, ABIM MOC |
This course offers a comprehensive update on the diagnosis and management of chronic spontaneous urticaria (CSU), a burdensome skin condition marked by recurrent hives and/or angioedema. Participants will explore evidence-based diagnostic approaches that reduce unnecessary testing, examine the clinical relevance of CSU endotypes and biomarkers, and apply guideline-based treatment algorithms. The course also highlights the evolving therapeutic landscape—including BTK inhibitors, IL-4/IL-13 inhibitors, and mast cell–targeted therapies—with emphasis on mechanism of action, clinical trial data, safety, and patient selection. Designed for allergists, dermatologists, and pediatric dermatologists, seeking to improve diagnostic accuracy, personalizing treatment, and effectively integrating emerging therapies into practice.
Welcome to this CSU program. Before we begin, please answer a few questions to assess your current knowledge of disease mechanisms, patient impact, and treatment strategies.
This module reviews the clinical features, diagnostic criteria, and burden of chronic spontaneous urticaria (CSU), with guidance on differentiating it from similar conditions, minimizing diagnostic delays, and identifying endotypes in treatment-resistant cases.
This module outlines treatment strategies for CSU, with attention to efficacy, adverse effects, and use in special populations. Learners will review clinical data and the role of shared decision-making in optimizing care.
This module reviews the mechanisms and data behind emerging therapies for CSU, including BTK, IL-4/IL-13, KIT, TSLP, and MRGPRX2 pathway inhibitors. Key trials and potential roles in future treatment strategies are discussed.
Now that you’ve completed the modules, take this short assessment to check your understanding of CSU pathophysiology, diagnosis, and treatment planning.
This is a CSU patient with asthma, allergic rhinitis, and possible atopic dermatitis.
Review of CSU Fundamentals and Patient Case
CSU Highlights from Fall Clinical Dermatology Conference and ACAAI Annual Scientific Meeting (November/December 2025)
CSU Highlights from the AAAAI Annual Meeting (March 2026)
CSU Highlights from the AAD Annual Meeting (April 2026)
In light of the information reviewed and discussed during this program, please share an action plan that you will implement to improve the diagnosis and management for your patients with CSU.
